NEW YORK, June 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on breakthrough therapies, today announced that it has regained full ...
Positive EU regulatory conclusion achieved Oncology-focused clinical program Multi-country European trial footprint Clear line of sight to site activation and enrollment Near-term regulatory and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results